GlassScriptPhysician profile
Nancy Jean Kaplitz
NPI 1033258587
$967.16
in general payments reported to CMS, 2019-2025
11 companies · $52.22 in 2025
The $52.22 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $139 · 2021: $55.35 · 2022: $152 · 2023: $389 · 2025: $52.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $240.62 | 2020-2023 | Ongentys, Ingrezza |
| Abbvie INC. | $155.72 | 2023-2025 | |
| Nevro Corp. | $151.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.59 | 2023 | Quviviq |
| Genentech, INC. | $112.33 | 2019 | |
| Allergan, INC. | $57.06 | 2019-2021 | |
| Lilly USA, LLC | $37.20 | 2020-2023 | Emgality |
| Biogen, INC. | $25.88 | 2021 | |
| Tanabe Pharma America, INC. | $24.78 | 2019 | |
| Pfizer INC. | $21.50 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $15.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Kaplitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.